Good morning, all. We hope you’re hanging tough and that your week is off to a splendid start. As for the news cycle — things could be better. A new study on a medication used to treat COVID-19 contradicts its efficacy, and another pharmaceutical company recalled a batch of Metformin. Read on and keep taking care of yourself.
Remdesivir For COVID-19 Linked to Hepatotoxicity
The antiviral medication remdesivir (brand name Veklury) has been shown to shorten recovery time in patients with COVID-19. A study in the New England Journal of Medicine showed that the 538 people who took the drug recovered four days quicker than the control group and had a mortality rate of 7.1% compared to 11.9%. Good news, right? Not so fast.
Not only did 21% of remdesivir users report adverse effects, but another investigation, published in Clinical Infectious Diseases, noted that liver toxicity is a rare but severe side effect of remdesivir. A 64-year-old man was admitted to the hospital with COVID-19 and was given remdesivir on day 16. Five days later, his levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increased, which is a sign of liver toxicity. He stopped taking the drug, and his ALT and AST levels rapidly dropped.
While the researchers can’t say for sure that the remdesivir was the cause of the liver toxicity, they feel strongly about it. Of course, more studies will need to be conducted before anything conclusive is said.
More Metformin Recalls
On July 8, Lupin Pharmaceuticals Inc. voluntarily recalled all batches of Metformin Hydrochloride Extended-Release Tablets USP 500mg and 1,000mg as certain batches were above the Acceptable Daily Intake Limit for the impurity N-Nitrosodimethylamine (NDMA), a possible carcinogen.
Metformin is taken by patients with type-2 diabetes to control blood glucose levels. If you take this drug, click here to see which batches were recalled. If you have one of those bottles, consult your doctor before stopping your medication.